Ocean Biomedical OCEA announced that its Scientific Co-founder, Jack Elias, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple-negative breast cancer.
The research demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs, which block T cells from contacting and killing the breast cancer tumor.
Additionally, the study provides further evidence of the potential impact of Ocean's anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth.
The paper reveals for the first time another complex pathway by which CHI3L1 inhibits the immune response to cancer, this time by inducing neutrophil recruitment and NETosis, which blocks T-cell infiltration.
The paper also provides another preclinical demonstration of the effectiveness of Ocean's Anti-CHI3L1 antibody in reducing tumor growth by targeting CHI3L1 and reversing the T-cell blockade.
This tumor control pathway, the paper asserts, is likely at work in a range of cancers beyond breast cancer, and "targeting CHI3L1 may promote anti-tumor immunity in various tumor types."
Prior research has established that elevated Chi3L1 levels are associated with many cancers, including glioblastoma, and may be targeted therapeutically.
Recent studies from Ocean Biomedical have demonstrated that CHI3L1 is a critical regulator of several key cancer-causing pathways, highlighting its ability to inhibit tumor cell death (apoptosis), its inhibition of the expression of the tumor suppressors P53, PTEN, retinoblastoma 1, and Keap1 and its stimulation of the B-RAF protooncogene.
Price Action: OCEA shares closed at $0.82 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
